Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label Study to Investigate the Tolerability and Safety of IBI310 Alone or in Combination With Sintilimab in Treatment of Patients With Advanced Solid Tumors.

Trial Profile

A Phase I, Open-Label Study to Investigate the Tolerability and Safety of IBI310 Alone or in Combination With Sintilimab in Treatment of Patients With Advanced Solid Tumors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Sintilimab (Primary)
  • Indications Malignant melanoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Innovent Biologics
  • Most Recent Events

    • 18 Oct 2018 According to an Innovent Biologics media release, the first patient has been dosed in the trial.
    • 12 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 20 Aug 2018 Planned number of patients changed from 22 to 74.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top